Mosseri Marlio Charles
10% Owner · Nuvectis Pharma, Inc.
Every open-market stock purchase Mosseri Marlio Charles has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where those buys landed inside insider clusters and how the prices paid compare to where the stock trades now.
Where the buys stand today
- NVCTNuvectis Pharma, Inc.
7 purchases totalling $3.5M at an average of $7.03 per share. See all insider buying in NVCT →
Avg price paid$7.03Latest price—Market cap$618.9M
Cluster participation
Qualifying buys grouped with other insiders buying the same stock — the pattern this site exists to catch.
All reported buys
| Date | Ticker | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| Jun 30, 2026 | NVCTcluster | 50,000 | $18.32 | $916.0K | SEC ↗ |
| Oct 27, 2025 | NVCTcluster | 72,836 | $6.28 | $457.4K | SEC ↗ |
| Oct 24, 2025 | NVCTcluster | 35,034 | $6.15 | $215.5K | SEC ↗ |
| Oct 23, 2025 | NVCTcluster | 46,900 | $6.06 | $284.2K | SEC ↗ |
| Jun 18, 2025 | NVCTcluster | 28,043 | $8.05 | $225.7K | SEC ↗ |
| May 12, 2025 | NVCTcluster | 21,167 | $8.11 | $171.7K | SEC ↗ |
| Feb 7, 2025 | NVCTcluster | 240,000 | $5.00 | $1.2M | SEC ↗ |
Follow new qualifying clusters involving Mosseri Marlio Charles or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from Mosseri Marlio Charles's Form 4 filings on SEC EDGAR (CIK 1806384) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.